TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21741060
Drug: IGFBP-1 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGFBP-1 levels in T2DM subjects (21.7 ± 3.5 ng/mL)
Study: 21741060
Drug: IGFBP-1 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGFBP-1 levels in NGT subjects with insulin resistance (25.5 ± 6.5 ng/mL)
Study: 21741060
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance association with IGFBP-1
Study: 18546895
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target concentration of 1.5 microg x ml(‐1)
Study: 18546895
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target concentration of 2.0 microg x ml(‐1)
Study: 12099919
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in a stroke unit (SU)
Study: 16060935
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in a general medical ward (GMW)
Study: 7674439
Drug: Small-movement therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-movement therapy
Study: 2116773
Drug: Monthly intravenous
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly intravenous methylprednisolone pulsing (steroid group)
Study: 31101627
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus lenalidomide (15 mg orally daily for 18 weeks)
Study: 31101627
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m2 IV on day 1 of weeks 1‐4 and repeated during weeks 12‐15 in responding patients)
Study: 29183037
Drug: Wiping plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wiping plus oral nutritional supplements (ONS)
Study: 29183037
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral care (Control)
Study: 25584004
Drug: Docetaxel 20
Normalized name: docetaxel 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 20 mg/m2 plus cisplatin 25 mg/m2 on days 1, 8, and 15, every 4 weeks
Study: 25584004
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m2 on day 1, every 3 weeks
Study: 23596781
Drug: Modified Shuyu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Shuyu Pill (MSP)
Study: 21253706
Drug: Zolpidem (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (single dose for the first seven post-operative nights)
Study: 21253706
Drug: Placebo (gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (gelatin capsule similar in appearance to zolpidem)
Study: 19731779
Drug: Integrative relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative relaxation training (IRT) - 12 weekly group sessions
Study: 18257345
Drug: Electrical plum-blossom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical plum-blossom needle therapy
Study: 14724106
Drug: Parnaparin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parnaparin (0.4 ml subcutaneously every 12 h for 7 days 12 h after thrombolysis, n=96)
Study: 14724106
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (100 U/kg x b.w. intravenous bolus, 1,000 U/h continuous infusion for 3 days, then subcutaneous 7500 U every 12 h for 4 days, n=90)
Study: 11759189
Drug: Oral montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast (n = 83)
Study: 11759189
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone 100 mcg three times daily (n = 41)
Study: 17532829
Drug: Oral montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast
Study: 3377519
Drug: Conventional dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dry gauze dressing (Curity) and antibiotic ointment (Polysporin)
Study: 23280675
Drug: Nicabate CQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicabate CQ Nicotine Replacement therapy (NRT)
Study: 21593301
Drug: Insulin targeting
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin targeting postprandial glycemia
Study: 21593301
Drug: Insulin targeting
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin targeting fasting/premeal glycemia
Study: 18283509
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment (2,940 nm) with variable pulse durations (1 ms to 2 ms) and energy densities (800 mJ/cm(2) to 1,400 mJ/cm(2)), 4 to 8 passes, single session
Study: 16488800
Drug: Facilitated PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated PCI with full-dose tenecteplase (n=829)
Study: 16488800
Drug: Facilitated PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated PCI with full-dose tenecteplase
Study: 14504416
Drug: Gabapentin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (300 mg initial dose, mean dosage 800 +/- 397 mg, range 300-1200 mg)
Study: 14504416
Drug: Ropinirole (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (0.5 mg initial dose, mean dosage 0.78 +/- 0.47 mg, range 0.25-1.50 mg)
Study: 9165958
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg.kg‐1 given 30 min pre-operatively
Study: 9165958
Drug: Trimeprazine 2
Normalized name: trimeprazine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimeprazine 2 mg.kg‐1 given 90 min pre-operatively
Study: 8238827
Drug: Increased fresh
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased fresh gas flow from 40 to 120 ml.kg‐1 x min‐1 (Group 1)
Study: 28108224
Drug: Elcatonin monotherapy
Normalized name: elcatonin
DrugBank: Elcatonin (DB13742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elcatonin monotherapy (20 units weekly)
Study: 28108224
Drug: Minodronic acid
Normalized name: Minodronic acid
DrugBank: Minodronic acid (DB06548)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Minodronic acid hydrate monotherapy (1 mg daily)
Study: 28108224
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (elcatonin and minodronic acid hydrate)
Study: 16825268
Drug: 10 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/day bovine colostrum protein concentrate (CPC)
Study: 16825268
Drug: 10 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/day whey protein (placebo)
Study: 8216665
Drug: Topical lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lignocaine 4 mg/kg (group A)
Study: 8216665
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol 10 mg/kg (group B)
Study: 28481726
Drug: RV3-BB vaccine
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RV3-BB vaccine (neonatal schedule)
Study: 28481726
Drug: RV3-BB vaccine
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RV3-BB vaccine (infant schedule)
Study: 29906071
Drug: Cashew apple
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cashew apple juice (240 mg/day)
Study: 29906071
Drug: Cashew apple
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cashew apple juice (120 mg/day)
Study: 18928091
Drug: Chinese herbs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbs for supplementing Shen, orally administered three days before and after ESWL
Study: 15946284
Drug: Oral cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cryotherapy using ice cubes before and during chemotherapy infusions.
Study: 8154822
Drug: Acute perioperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute perioperative normovolaemic haemodilution with retransfusion of autologous blood (900 ml taken preoperatively, replaced with 1000 ml of gelatin solution)
Study: 2484360
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 supplementation (2 mg daily)
Study: 29211857
Drug: Continued antiarrhythmic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued antiarrhythmic drug treatment (ADT ON)
Study: 29211857
Drug: Discontinued antiarrhythmic
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued antiarrhythmic drug treatment (ADT OFF)
Study: 28700482
Drug: Fu-Zheng-Qu-Zhuo oral
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fu-Zheng-Qu-Zhuo oral liquid (FZQZ)
Study: 23816199
Drug: Aftercare services
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aftercare services including treatment follow-up (home care or telephone follow-up), family psychoeducation, and patient social skills training provided by community mental health teams.
Study: 21714999
Drug: GAD‐alum (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD‐alum (20 μg, three injections)
Study: 21714999
Drug: GAD‐alum plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD‐alum plus alum (20 μg GAD‐alum, two injections and one of alum)
Study: 21714999
Drug: Alum (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum (three injections)
Study: 9203944
Drug: Hyperglycaemia (16-19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (16-19 mmol/l glucose)
Study: 9203944
Drug: Euglycaemia (5-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemia (5-8 mmol/l glucose)
Study: 7950736
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 g twice daily)
Study: 7950736
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drug (diclofenac 50 mg twice daily)
Study: 3389899
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous cannulae
Study: 26742304
Drug: PCIA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCIA group (Ondansetron 8 mg IV for 5 min, tramadol 1.5 mg/kg infusion)
Study: 26742304
Drug: PCEA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA group (Ropivacaine 3 mg intrathecal, epidural infusion of Ropivacaine 0.1% and Sufentanil 50 ug)
Study: 2815966
Drug: Trivalent split
Normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent split virus vaccine
Study: 2815966
Drug: Monovalent A/Taiwan/86(H1N1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent A/Taiwan/86(H1N1) vaccine
Study: 31663462
Drug: Smart Pill
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smart Pill Bottle (SPB) with pharmacist intervention
Study: 29354972
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of central‐square needling technique of thumb‐tack needles with routine therapy of acupuncture, moxibustion and tuina
Study: 29354972
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy of acupuncture, moxibustion and tuina
Study: 23242570
Drug: EMLA(®) cream
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA(®) cream (2.5 g applied for a minimum of 30 min before venipuncture)
Study: 18362868
Drug: d‐MPH‐ER (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH‐ER (20 mg/day)
Study: 18362868
Drug: d,l‐MPH‐ER (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l‐MPH‐ER (36 mg/day)
Study: 18362868
Drug: d‐MPH‐ER and
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH‐ER and d,l‐MPH‐ER
Study: 16412546
Drug: High potency
Normalized name: High Potency B+C
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High potency neuroleptic agents (risperidone/ziprasidone/aripiprazole)
Study: 16412546
Drug: Low potency
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low potency neuroleptic agents (quetiapine/olanzapine)
Study: 12937308
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg) and clopidogrel (75 mg) daily
Study: 11012555
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride 550 mg in solution alone
Study: 11012555
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride 550 mg in solution after 10 mg i.v. dose of metoclopramide
Study: 11012555
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride 550 mg in solution after 30 mg oral dose of propantheline
Study: 8598838
Drug: Saquinavir (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir (1800 mg per day) plus zidovudine (600 mg per day) and zalcitabine (2.25 mg per day)
Study: 8598838
Drug: Three-drug combination
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug combination (saquinavir, zidovudine, zalcitabine)
Study: 1412099
Drug: Mask without
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mask without Venturi attachment at 2, 4, and 6 l/min
Study: 1412099
Drug: Mask with
Normalized name: SULFUR 10 g in 100 mL TOPICAL CREAM [Soothing Antiseptic Mask with Sulfur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mask with Venturi attachments (24% and 28%) at 2 and 4 l/min
Study: 6443774
Drug: Cefsulodin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefsulodin (various dosages, including 250 mg every 6 hr)
Study: 11984383
Drug: Isopropyl alcohol
Normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isopropyl alcohol (IPA) inhalation
Study: 26138593
Drug: Clazakizumab 25
Normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab 25 mg plus MTX
Study: 26138593
Drug: Clazakizumab 100
Normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab 100 mg plus MTX
Study: 26138593
Drug: Clazakizumab 200
Normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab 200 mg plus MTX
Study: 26138593
Drug: Clazakizumab 100
Normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab 100 mg monotherapy
Study: 26138593
Drug: Clazakizumab 200
Normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab 200 mg monotherapy
Study: 26138593
Drug: All clazakizumab
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All clazakizumab groups (25 mg, 100 mg, 200 mg)
Study: 26138593
Drug: Clazakizumab treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab treatment groups
Study: 11518061
Drug: WS 5570
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS 5570 Hypericum perforatum extract 300 mg
Study: 11518061
Drug: WS 5570
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS 5570 Hypericum perforatum extract 600 mg
Study: 29319408
Drug: Tremella fuciformis
Normalized name: TREMELLA FUCIFORMIS WHOLE
DrugBank: Tremella fuciformis whole (DB14359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremella fuciformis 600 mg/day, n=30
Study: 29319408
Drug: Tremella fuciformis
Normalized name: TREMELLA FUCIFORMIS WHOLE
DrugBank: Tremella fuciformis whole (DB14359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremella fuciformis 1200 mg/day, n=30
Study: 29319408
Drug: Tremella fuciformis
Normalized name: TREMELLA FUCIFORMIS WHOLE
DrugBank: Tremella fuciformis whole (DB14359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremella fuciformis (both doses combined)
Study: 29319408
Drug: Tremella fuciformis
Normalized name: TREMELLA FUCIFORMIS WHOLE
DrugBank: Tremella fuciformis whole (DB14359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremella fuciformis (both doses)
Study: 26571900
Drug: Shujing massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shujing massage therapy
Study: 26571900
Drug: Medication with
Normalized name: EUGENOL 850 mg in 1 mL DENTAL LIQUID [Walgreens Natural Eugenol/Toothache Medication with cotton pellets and tweezers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication with estazolam (1 mg orally before sleep)
Study: 19064533
Drug: 10.2 mg
Normalized name: serine 10.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.2 mg ELTP/d in a yogurt beverage for 8 weeks
Study: 12680883
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg intranasal mometasone furoate (MF) once daily for 2 weeks
Study: 12680883
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg intranasal mometasone furoate (MF)
Study: 7030372
Drug: Penbutolol, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol, 80 mg once a day
Study: 7030372
Drug: Hydrochlorothiazide, 100
Normalized name: HydroCHLOROthiazide, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide, 100 mg once a day
Study: 26064677
Drug: Caloric Titration
Normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caloric Titration Method (CTM)
Study: 23914211
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 mg kg(‐1) for the first 10 min, followed by continuous infusion of dexmedetomidine (0.2‐0.7 μg kg(‐1) h(‐1))
Study: 23914211
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg kg(‐1) h(‐1) for the first 10 min, followed by continuous infusion of midazolam (0.05‐0.15 μg kg(‐1) h(‐1))
Study: 20233198
Drug: Prior administration
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior administration of terbutaline
Study: 18802369
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid therapy (specific types not detailed, e.g., hydroxyethylstarch)
Study: 16482787
Drug: Subcutaneously-placed, round,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously-placed, round, saline-filled prosthesis with a textured surface (Siltex and Microcell implants)
Study: 16482787
Drug: Reoperation for
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reoperation for capsular contracture (open capsulotomy with or without implant exchange, closed compression capsulotomy)
Study: 16482787
Drug: Large-pore implants
Normalized name: Oxy Deep Pore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-pore implants
Study: 12672710
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral calcium load with serum 25OHD at 86.5 nmol/L
Study: 12672710
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral calcium load with serum 25OHD at 50 nmol/L
Study: 10819857
Drug: Atosiban (6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (6.75 mg intravenous bolus, 300 microg/min for 3 hours, then 100 microg/min intravenously)
Study: 10819857
Drug: Ritodrine (0.10‐0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrine (0.10‐0.35 mg/min intravenously)
Study: 1869345
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (sulpiride 200 mg)
Study: 1869345
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (sulpiride 200 mg)
Study: 3160869
Drug: High-dose medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medroxyprogesterone acetate (HD-MPA) 1200 mg p.o., b.i.d.
Study: 3160869
Drug: High-dose medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medroxyprogesterone acetate (HD-MPA)
Study: 24325365
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) formulation, 100 mg administered three times at 6-h intervals
Study: 24325365
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) formulation, 300 mg administered once to fasting subjects
Study: 24325365
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) formulation, 300 mg administered once to fed subjects
Study: 21883710
Drug: Systemic antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotic therapy (n=10)
Study: 21883710
Drug: No prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prior antibiotic therapy (n=10)
Study: 18313905
Drug: Novel lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel lipid formulation containing fenofibrate in omega‐3 oil
Study: 2880497
Drug: Beta-blocking drugs
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocking drugs
Study: 7031855
Drug: Subunit influenza
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit influenza vaccine (A/Victoria/75 and B/Hongkong/73)
Study: 27053642
Drug: Imitation-based speech
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imitation-based speech therapy for 6 weeks